VVOS news

Vivos Therapeutics, Inc. has received a letter from The Nasdaq Stock Market confirming its continued compliance with the stockholders' equity standard following a major equity transaction, averting immediate delisting risks.

The company announced the grand opening of a Nevada facility expected to double revenue capacity to $10 million. This expansion aims to meet rapidly rising patient demand and referrals in the Las Vegas market.

Vivos Therapeutics announced its intent to file a registration statement for a proposed rights offering that would distribute transferable subscription rights to shareholders, with an exercise price of at least $1.25 per share or 20% above market price. The offering structure includes a nine-month e…

Vivos Therapeutics issued a convertible promissory note for up to $5 million to V-CO Investors 4 LLC dated May 7, 2026, with an initial $500,000 advance to fund operations ahead of an anticipated $5.5 million equity financing. The note carries a 10% bridge financing fee and 15% interest accrues only…